Logo Logo Logo Logo Logo
  • About Us
    • Our Mission
    • About Odylia
    • Our Board
    • Our Team
  • Our Impact
    • Odylia Impact Report
    • Rare Disease Awareness Events
    • Newsletter
    • News
  • Support Odylia
    • Donate
    • Other ways to Give
    • Change for A Cure
    • Getting Involved
  • Pipeline & Services
    • Odylia Pipeline & Services Overview
    • Odylia Pipeline
      • RPGRIP1 Gene Therapy
      • USH1C Gene Therapy
      • NPHP1 Gene Therapy
    • Brydge Solutions
    • Anc80 Resources
  • Resources
    • The Odylia Library
    • The Odylia Collective
    • Rare Disease Resources
    • Fundraising Resources
    • Webinars and Presentations
  • Donate
  • About Us
    • Our Mission
    • About Odylia
    • Our Board
    • Our Team
  • Our Impact
    • Odylia Impact Report
    • Rare Disease Awareness Events
    • Newsletter
    • News
  • Support Odylia
    • Donate
    • Other ways to Give
    • Change for A Cure
    • Getting Involved
  • Pipeline & Services
    • Odylia Pipeline & Services Overview
    • Odylia Pipeline
      • RPGRIP1 Gene Therapy
      • USH1C Gene Therapy
      • NPHP1 Gene Therapy
    • Brydge Solutions
    • Anc80 Resources
  • Resources
    • The Odylia Library
    • The Odylia Collective
    • Rare Disease Resources
    • Fundraising Resources
    • Webinars and Presentations
  • Donate

10 Mar Launch of Odylia’s Newsletter

Posted at 08:43h in Press Releases by Odylia Media

Atlanta, GA March 10th, 2021 – Odylia is pleased to announce the launch of our newsletter which can be read here. In this edition, we discuss how Odylia is reimagining drug development for rare diseases and our 2020 highlights.  The newsletter will be sent a few times a year, so please sign up for future editions here.

Print page


Latests Posts
  • Critical Path Institute Awards $249,719 Grant to Odylia Therapeutics to Advance Gene Therapy for USH1C-Associated Vision Loss

    20 May, 2026
  • Wendy Erler

    Odylia Therapeutics Welcomes Wendy Erler to Board of Directors

    22 April, 2026
  • Comend and Odylia Partner to Advance Rare Disease Drug Development with Innovative Patient-Driven Platform

    13 May, 2025
Categories
  • Press Releases
  • Uncategorized
Tags
Alexion Amgen Prize Board of Directors Brydge Solutions Comend Concordia Summit Critical Path Institute February 2025 gene therapy Joy Cavagnaro marketplace MIT Solve nephrocystin-1 nephronophthisis NPHP1 NPHP1 Family Foundation Odylia patient groups PURA purine-rich element-binding protein alpha purine rich rare disease Rare Disease Day Sarepta Senior-Loken Syndrome SKS Smith Kingsmore Smith Kingsmore Foundation The Collective The Odylia Collective USH1C Wendy Erler
Services
  • Odylia Pipeline & Services Overview
  • Brydge Solutions

Visit Odylia's linked in page Visit Odylia's linked in page

Science
  • Research and Development
  • Our Mission
Resources
  • The Odylia Library
  • The Odylia Collective
  • Resources
  • Webinars and Presentations
  • Clinical Trials
Latest News
  • Critical Path Institute Awards $249,719 Grant to Odylia Therapeutics to Advance Gene Therapy for USH1C-Associated Vision Loss
  • Odylia Therapeutics Welcomes Wendy Erler to Board of Directors
  • Comend and Odylia Partner to Advance Rare Disease Drug Development with Innovative Patient-Driven Platform
Odylia Therapeutics logo

© 2025 Odylia Therapeutics | Registered 501(c)(3). EIN: 82-2120760 | Site by Hester Designs